TL;DR
This review synthesizes evidence on the impact of delayed treatment for localized prostate cancer, finding that for most patients, delays of several months to even years are safe, especially with active surveillance or neoadjuvant hormonal therapy. This provides crucial guidance for clinicians and patients navigating treatment timing decisions.
What Problem Does This Paper Address?
The paper addresses the common clinical challenge of determining safe and effective timelines for initiating definitive treatment (radical prostatectomy or radiotherapy) for localized prostate cancer. Delays in diagnosis, work-up, and treatment initiation are frequent due to logistical issues, patient preferences, and, notably, the COVID-19 pandemic, which highlighted the need for evidence-based recommendations on treatment timing. While guidelines exist, they often lack a detailed rationale. The core problem is the absence of definitive, level I evidence specifically answering "When should I start radiation or undergo surgery?" for localized prostate cancer, leaving a gap in clinical decision-making.
Methods
The authors conducted a narrative review of the literature. They searched PubMed for studies published from January 2000 to June 2020 using keywords related to delayed or deferred treatment for prostate cancer, surgery, and radiation. They focused on full papers that provided median or mean delay durations and clear comparison groups. The review categorized data into two main types:
- Randomized Controlled Trials (RCTs): These included trials where treatment arms had staggered timings or compared immediate versus delayed treatment. The interpretation of RCTs relied on assumptions: if immediate treatment showed improvement, the safe delay must be shorter; if delayed treatment was comparable or better, the delay was likely safe.
- Post-hoc Retrospective Studies: These studies evaluated the impact of delays from biopsy to definitive treatment.
Due to heterogeneity in data collection, patient selection, and definitions of delay, a meta-analysis or formal systematic review was deemed inappropriate. The authors did not formally assess quality or bias.
Datasets
The paper does not introduce new datasets or benchmarks. Instead, it synthesizes data from existing published studies, primarily randomized controlled trials (RCTs) and retrospective studies. The authors reference a total of 39 retrospective studies and 26 RCTs, with specific details of many RCTs presented in Table 1.
Key Insights and Ideas
- "Safe" Delays are More Common Than Feared: For many patients with localized prostate cancer, delays of several months to even years in initiating definitive treatment are likely safe and may not negatively impact oncologic outcomes.
- Active Surveillance and Neoadjuvant Hormonal Therapy are Key: For low-risk disease, active surveillance (AS) is a viable option, with delays of up to 7 years potentially being safe. For intermediate- and high-risk disease, neoadjuvant androgen deprivation therapy (ADT) can safely facilitate delays of up to 8 months before radiotherapy, often improving outcomes.
- Risk Stratification is Crucial: The acceptable delay duration is highly dependent on the patient's risk category (very low, low, intermediate, high). High-risk patients generally require more timely intervention, though ADT can still provide a buffer.
- Post-Prostatectomy Radiotherapy: In the post-operative setting, early adjuvant radiotherapy can often be omitted in favor of salvage radiotherapy initiated upon biochemical recurrence (PSA failure), particularly for patients with limited high-risk features.
- Heterogeneity of Studies Limits Definitive Conclusions: The wide variation in study designs, definitions of delay, patient populations, and outcome measures makes it challenging to establish precise, universally applicable timeframes.
Key Results
- Neoadjuvant ADT Before RT: RCTs suggest that delaying RT up to 7-8 months, when preceded by ADT, is safe for intermediate- to high-risk prostate cancer, with some studies showing improved outcomes compared to immediate RT alone.
- Neoadjuvant ADT Before RP: Studies comparing neoadjuvant ADT before radical prostatectomy (RP) did not consistently show improved survival, suggesting ADT is not routinely recommended prior to RP. However, it can be safely used to delay RP for up to 3-8 months.
- RP vs. Observation: Large RCTs (SPCG-4, PIVOT, PROTECT) indicate that for localized prostate cancer, RP generally offers improved overall survival and reduced risk of metastasis and progression compared to observation or active surveillance, even with long follow-up periods. For favorable-risk disease, delays of up to 7 years on AS may be safe.
- Post-Prostatectomy RT: Multiple RCTs suggest that post-operative radiotherapy can be safely delayed until PSA failure occurs (PSA 0.1-0.2), with no difference in biochemical progression-free survival compared to immediate adjuvant RT. However, the role of delaying RT in patients with higher risk features remains less clear.
- Retrospective Studies: A large number of retrospective studies (39 in total) generally supported the findings from RCTs, with many indicating that delays beyond 6-12 months may adversely impact outcomes, particularly for high-risk patients. However, these studies often had limitations in defining delays and patient selection.
Limitations and Future Work
- Limitations:
- Absence of Level I Evidence: The paper highlights the lack of prospective phase III RCTs specifically designed to answer the question of acceptable delay periods.
- Heterogeneity: Significant variability exists in how "delay" is defined, patient selection criteria, practice patterns, and outcome measures across studies, precluding meta-analysis.
- Bias: The authors acknowledge the inherent biases in retrospective studies and the potential for selection bias in RCTs (e.g., healthier patients included).
- Generalizability: Patients in RCTs may be healthier than the general population, potentially leading to overestimation of delayed treatment benefits due to competing risks.
- Newer Therapies/Imaging: The review is based on data up to June 2020, and newer drugs or advanced imaging techniques might allow for earlier detection of progression or more refined management strategies.
- Future Work:
- The authors express hope that their review will facilitate transparent communication and evidence-based recommendations.
- Given the unlikelihood of future RCTs specifically designed for this question, this narrative review aims to clarify the reasoning behind current recommendations.
- The paper suggests that further research might focus on refining the definition of "safe" delays for specific patient subgroups and exploring the role of newer technologies in managing treatment timing.
Summary updated